![Wael Fayad](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Wael Fayad
Direktor/Vorstandsmitglied bei
Crown Laboratories, Inc.
Profil
Wael Fayad is the founder of Accoy Pharmaceuticals, Inc. (founded in 2015).
He is currently the Director at Crown Laboratories, Inc. (since 2020) and a Partner at Hildred Capital Management LLC (since 2018).
Previously, he served as the Chairman of Enumeral Biomedical Holdings, Inc. (2017-2018) and held a position as Vice President-Global Business Development at Forest Laboratories, Inc. Mr. Fayad holds an MBA from Concordia University (conferred in 1993) and an undergraduate degree from the American University of Beirut (conferred in 1989).
Aktive Positionen von Wael Fayad
| Unternehmen | Position | Beginn |
|---|---|---|
Hildred Capital Management LLC
 Hildred Capital Management LLC Investment ManagersFinance Hildred Capital invests in middle market companies located in the United States with an enterprise value of USD 50 - 500 million and revenues of USD 10 - 100 million. The firm targets companies operating in the fields of healthcare services, consumer products, information technology, medical devices and pharmaceuticals products sectors. It provides financing for growth and buyout stage capital transactions with an investment size of USD 25 - 300 million. The firm also acquires majority and minority stake positions. | Private Equity Investor | 01.05.2018 |
Crown Laboratories, Inc.
 Crown Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets consumer skincare, prescription dermatology and aesthetic treatment products | Direktor/Vorstandsmitglied | 01.02.2020 |
Ehemalige bekannte Positionen von Wael Fayad
| Unternehmen | Position | Ende |
|---|---|---|
Accoy Pharmaceuticals, Inc. | Gründer | 01.09.2019 |
| ENUMERAL BIOMEDICAL HOLDINGS INC | Vorstandsvorsitzender | 29.06.2017 |
| FOREST LABORATORIES, INC. | Corporate Officer/Principal | - |
Ausbildung von Wael Fayad
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
12
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Crown Laboratories, Inc.
Crown Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets consumer skincare, prescription dermatology and aesthetic treatment products | Health Technology |
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells drug products | Health Technology |
Enumeral Biomedical Holdings, Inc.
 Enumeral Biomedical Holdings, Inc. BiotechnologyHealth Technology Develops novel antibody immunotherapies designed to help immune system attack diseased cells | Health Technology |
Concordia University
 Concordia University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
American University of Beirut
 American University of Beirut Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hildred Capital Management LLC
Hildred Capital Management LLC Investment ManagersFinance Hildred Capital invests in middle market companies located in the United States with an enterprise value of USD 50 - 500 million and revenues of USD 10 - 100 million. The firm targets companies operating in the fields of healthcare services, consumer products, information technology, medical devices and pharmaceuticals products sectors. It provides financing for growth and buyout stage capital transactions with an investment size of USD 25 - 300 million. The firm also acquires majority and minority stake positions. | Finance |
Accoy Pharmaceuticals, Inc. |
